<DOC>
	<DOCNO>NCT01902225</DOCNO>
	<brief_summary>This multi-center , single arm , open-label , Phase I dose-finding preliminary efficacy study combination histone deacetylase inhibitor romidepsin ( Istodax® ) combination doxorubicin HCl liposomal ( Doxil® ) adult patient relapse refractory cutaneous T-cell lymphoma least 2 line skin-directed therapy one prior line systemic therapy . Patients treat Doxil 20mg/m2 day 1 romidepsin 8-14mg/m2 day 1 , 8 15 , every 28 day , 2 cycle beyond best response , 8 cycle , disease progression intolerability whichever come first . Importanly , doxil administer prior romidepsin day1 cycle . Patients follow disease progression death whichever come first .</brief_summary>
	<brief_title>Phase I Dose-finding Preliminary Efficacy Study Istodax® Combination With Doxil® Treatment Adults With Relapsed Refractory Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>This multi-center , single arm , open-label , Phase I dose-finding preliminary efficacy study combination histone deacetylase inhibitor romidepsin ( Istodax® ) combination doxorubicin HCl liposomal ( Doxil® ) adult patient relapse refractory cutaneous T-cell lymphoma least one prior line systemic therapy . STUDY ENDPOINTS : Primary : MTD determine standard `` 3+3 '' dose escalation romidepsin fix dose doxorubicin HCl liposomal . Participants follow throughout therapy adverse event record , grade , give likelihood relevance study therapy . Toxicity grade NCI Common Toxicity Criteria Adverse Events ( CTCAE ) version 4.0 . Secondary : - Response assess global response score integrate change skin disease measure modified severity-weighted assessment tool ( mSWAT ) score , change lymph node size , change visceral disease , change peripheral blood Sézary cell flow cytometry . CR/PR assignment require confirmatory assessment 4 week . Skin score , clinical lymph node , liver spleen exam , Sézary cell count assessment occur Day 1 cycle . Contrasted CT scan neck , chest , abdomen pelvis perform screening patient . In patient lymphadenopathy and/or organomegaly screening , contrast CT scan neck , chest , abdomen , pelvis occur end every third cycle therapy , within 1 week cycle 8 completion , every 6 month one year maximal response . All patient contrast CT scan neck , chest , abdomen , pelvis time concern disease progression lymph node and/or viscera.TTR time first romidepsin dose time document objective response ( PR/CR ) . DOR time first objective response ( PR CR ) disease progression . - TTP measure time first romidepsin dose disease progression . - Pruritus assess monthly use 100 mm visual analog scale . Quality life assess monthly FACT-G , Skindex-29 , ItchyQOL questionnaires . Exploratory : Skin lesion punch biopsied ( two contiguous 5mm biopsy ) prior begin therapy standard care care . Any leftover tissue collect research consent patient . Optional single 5mm punch biopsy obtain day 15 Cycle 2 infusion romidepsin , disease relapse .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Able understand voluntarily sign informed consent form . 2 . Age ≥18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Biopsyproven , measurable , Stage IBIVB relapse refractory cutaneous Tcell lymphoma 2 line skindirected therapy one prior line systemic therapy ( Note : extracorporeal photopheresis consider systemic therapy study ) 5 . All cancer therapy , include radiation , hormonal therapy surgery , must discontinue least 4 week prior treatment study . The exception participant erythroderma corticosteroid prolong period time ( &gt; 60 day ) without change may continue use either low dose systemic steroid ( equivalent &lt; 10 mg per day prednisone ) low potency topical steroid eligible study frequency dosage steroid change 60 day prior study . These participant continue dose systemic/topical steroid throughout study period unless achieve complete response time steroid discontinue . 6 . ECOG performance status ≤ 2 study entry . 7 . Laboratory test result within range : Absolute neutrophil count ≥750/mm³ Platelet count≥75,000/mm³ Total bilirubin ≤ 2 x ULN AST ( SGOT ) ALT ( SGPT ) ≤ 3 x ULN . Creatinine &lt; 2 mg/dL 8 . Disease free prior malignancy ≥ 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma situ cervix breast . Patients early stage prostate cancer clinical surveillance without therapy eligible 9 . Negative serum pregnancy test time enrollment female childbearing potential . 10 . For male female childproducing potential , use effective contraceptive method study include 2 method contraception , one condom . 11 . Life expectancy &gt; 90 day . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use experimental drug therapy within 28 day baseline except topical therapy mycosis fungoides must discontinue 14 day prior initiation study therapy . 5 . Prior allogeneic hematopoietic cell transplant . 6 . Prior solid organ transplant . 7 . Cumulative anthracycline exposure great 300 mg/m2 doxorubicin equivalent . 8 . Known active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive prior hepatitis B virus vaccination eligible . 9 . Central nervous system meningeal involvement 10 . Any known cardiac abnormality include : Congenital long QT syndrome Baseline QTc interval ≥ 450 millisecond ; Myocardial infarction within 6 month C1D1 . Subjects history myocardial infarction 6 12 month prior C1D1 asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate Other significant ECG abnormality include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian Class II IV . In patient doubt , patient stress image study , abnormal , angiography define whether CAD present An ECG record screen show evidence cardiac ischemia ( ST depression ≥2 mm , measure isoelectric line ST segment ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition ( see Appendix 10 ) and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or MRI A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause Uncontrolled hypertension , i.e. , blood pressure ( BP ) ≥160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion Any cardiac arrhythmia require antiarrhythmic medication ( exclude stable dos betablockers ) Any cardiac finding deem ineligible discretion investigator 11 . Patients take drug lead significant QT prolongation unable stop drug prior treatment 12 . Concomitant use CYP3A4 inhibitor inducer unless able stop medication ( ) prior start study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>T-Cell</keyword>
	<keyword>Cutaneous</keyword>
	<keyword>Doxil</keyword>
	<keyword>romidepsin</keyword>
	<keyword>skin</keyword>
</DOC>